• Kala Bio fiscal 2025 net loss narrowed 29.9% to $27 million.
• Operating loss improved to $39.2 million from $41 million.
• Cash and cash equivalents fell to $7.6 million as of Dec. 31, 2025, down from $51.2 million.
• Company exited KPI-012 and MSC-S development in September 2025 after CHASE Phase 2b missed primary endpoints, shifting focus to monetizing legacy biologics assets and building an on-premises AI platform business under an exclusive Researgency license.
• Outlook: existing cash expected to fund operations into first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-043782), on April 15, 2026, and is solely responsible for the information contained therein.